SCHEMBL4538786

SCHEMBL4538786

CS(=O)(=O)Nc1cnc2cc(Br)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 6/20 0.51
SLC22A12 Q96S37 1/20 0.47
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 1/20 0.44
MET P08581 5/20 0.43
NPC1 O15118 1/20 0.43
JAK2 O60674 1/20 0.43
RAB9A P51151 1/20 0.43
ALOX12 P18054 1/20 0.42
MAPK10 P53779 1/20 0.41
HTT P42858 3/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KCNH2 Q12809 1/20 0.41
AURKA O14965 1/20 0.40
AURKB Q96GD4 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23892289 0.79 CYP1A2 (0.46) ALPLKDM4EHTTMEN1KMT2A
SCHEMBL695033 0.77 BRPF1 (0.51) SLC22A12ALDH1A1KDM4EHTTLMNA
SCHEMBL15534129 0.76 RAB9A (0.51) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL17375043 0.72 SLC22A12 (0.49) SLC22A12ALDH1A1KDM4ENPC1LMNA
SCHEMBL8996768 0.72 MET (0.47) ALDH1A1KDM4EMETMAPK10HTT
SCHEMBL17375009 0.71 BRPF1 (0.46) ALDH1A1METNPC1JAK2RAB9A
SCHEMBL29612573 0.70 CYP1A2 (0.57) ALDH1A1KDM4EHTTMAPTSMN1; SMN2
SCHEMBL2445484 0.70 MET (0.81) METKCNH2
SCHEMBL4540744 0.70 CYP1A2 (0.57) ALDH1A1KDM4EHTTMAPTSMN1; SMN2
SCHEMBL4541208 0.69 ABL1 (0.60) JAK2RAB9AALOX12HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014008223-A2 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-01-09 WO disclosed
EP-2637660-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2013-09-18 EP disclosed
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2013-09-12 US disclosed
WO-2012064642-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 ALPL 4816/4885SLC22A12 2409/4885ALDH1A1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.